We hypothesized that by increasing the secretion of the endogenous GLP-1 and the absorption of a GLP-1 analog by oral administration of this formulation we will have a stronger impact on NAFLD-associated metabolic syndrome than the subcutaneous injection of the GLP-1 analog, preventing the progression into more severe disease states. This evidence concerns the gene GLP1R and metabolic syndrome.